vs
Side-by-side financial comparison of Foghorn Therapeutics Inc. (FHTX) and UPEXI, INC. (UPXI). Click either name above to swap in a different company.
Foghorn Therapeutics Inc. is the larger business by last-quarter revenue ($9.2M vs $8.1M, roughly 1.1× UPEXI, INC.). Foghorn Therapeutics Inc. runs the higher net margin — -234.3% vs -2222.1%, a 1987.8% gap on every dollar of revenue. On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs 101.0%). Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs 24.2%).
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.
FHTX vs UPXI — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $9.2M | $8.1M |
| Net Profit | $-21.7M | $-178.9M |
| Gross Margin | — | 83.3% |
| Operating Margin | -258.2% | -2177.9% |
| Net Margin | -234.3% | -2222.1% |
| Revenue YoY | 223.8% | 101.0% |
| Net Profit YoY | -11.1% | -13649.6% |
| EPS (diluted) | $-0.35 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.2M | $8.1M | ||
| Q3 25 | $8.2M | $9.2M | ||
| Q2 25 | $7.6M | $4.3M | ||
| Q1 25 | $6.0M | $3.2M | ||
| Q4 24 | $2.9M | $4.0M | ||
| Q3 24 | $7.8M | $4.4M | ||
| Q2 24 | $6.9M | $5.0M | ||
| Q1 24 | $5.0M | $5.2M |
| Q4 25 | $-21.7M | $-178.9M | ||
| Q3 25 | $-15.8M | $66.7M | ||
| Q2 25 | $-17.9M | $-6.9M | ||
| Q1 25 | $-18.8M | $-3.8M | ||
| Q4 24 | $-19.5M | $-1.3M | ||
| Q3 24 | $-19.1M | $-1.6M | ||
| Q2 24 | $-23.0M | $-15.7M | ||
| Q1 24 | $-25.0M | $-4.1M |
| Q4 25 | — | 83.3% | ||
| Q3 25 | — | 89.6% | ||
| Q2 25 | — | 79.4% | ||
| Q1 25 | — | 49.3% | ||
| Q4 24 | — | 74.3% | ||
| Q3 24 | — | 67.3% | ||
| Q2 24 | — | 31.0% | ||
| Q1 24 | — | 24.3% |
| Q4 25 | -258.2% | -2177.9% | ||
| Q3 25 | -226.9% | — | ||
| Q2 25 | -279.2% | -151.7% | ||
| Q1 25 | -385.0% | -113.5% | ||
| Q4 24 | -840.5% | -26.8% | ||
| Q3 24 | -305.5% | -30.6% | ||
| Q2 24 | -386.6% | -265.2% | ||
| Q1 24 | -558.3% | -96.5% |
| Q4 25 | -234.3% | -2222.1% | ||
| Q3 25 | -194.4% | 722.4% | ||
| Q2 25 | -237.3% | -161.5% | ||
| Q1 25 | -316.4% | -121.2% | ||
| Q4 24 | -682.9% | -32.5% | ||
| Q3 24 | -244.9% | -37.3% | ||
| Q2 24 | -333.6% | -312.4% | ||
| Q1 24 | -495.4% | -78.9% |
| Q4 25 | $-0.35 | — | ||
| Q3 25 | $-0.25 | $0.76 | ||
| Q2 25 | $-0.28 | $0.83 | ||
| Q1 25 | $-0.30 | $-2.87 | ||
| Q4 24 | $-0.23 | $-1.24 | ||
| Q3 24 | $-0.31 | $1.55 | ||
| Q2 24 | $-0.45 | $-15.66 | ||
| Q1 24 | $-0.59 | $-4.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-108.5M | $48.7M |
| Total Assets | $198.1M | $271.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.9M | — | ||
| Q3 25 | $89.3M | — | ||
| Q2 25 | $72.6M | — | ||
| Q1 25 | $61.0M | — | ||
| Q4 24 | $55.5M | — | ||
| Q3 24 | $57.7M | — | ||
| Q2 24 | $138.9M | — | ||
| Q1 24 | $79.3M | — |
| Q4 25 | $-108.5M | $48.7M | ||
| Q3 25 | $-89.7M | $210.8M | ||
| Q2 25 | $-76.7M | $90.1M | ||
| Q1 25 | $-61.7M | $1.9M | ||
| Q4 24 | $-45.5M | $3.8M | ||
| Q3 24 | $-28.3M | $5.0M | ||
| Q2 24 | $-14.3M | $6.5M | ||
| Q1 24 | $-97.5M | $22.1M |
| Q4 25 | $198.1M | $271.1M | ||
| Q3 25 | $205.0M | $419.7M | ||
| Q2 25 | $226.2M | $123.8M | ||
| Q1 25 | $258.7M | $15.1M | ||
| Q4 24 | $284.0M | $17.5M | ||
| Q3 24 | $308.4M | $18.6M | ||
| Q2 24 | $328.6M | $23.5M | ||
| Q1 24 | $255.0M | $56.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-22.3M | $-2.7M |
| Free Cash FlowOCF − Capex | — | $-2.7M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | 0.0% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-22.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-22.3M | $-2.7M | ||
| Q3 25 | $-18.9M | $-9.8M | ||
| Q2 25 | $-21.0M | $-8.4M | ||
| Q1 25 | $-24.0M | $-778.7K | ||
| Q4 24 | $-24.5M | $-1.4M | ||
| Q3 24 | $-21.0M | $-2.0M | ||
| Q2 24 | $-25.5M | $-101.4K | ||
| Q1 24 | $-29.3M | $783.5K |
| Q4 25 | — | $-2.7M | ||
| Q3 25 | — | $-9.8M | ||
| Q2 25 | $-21.0M | $-8.8M | ||
| Q1 25 | $-24.0M | $-809.3K | ||
| Q4 24 | $-25.0M | — | ||
| Q3 24 | $-21.3M | $-2.1M | ||
| Q2 24 | $-25.6M | $-1.0M | ||
| Q1 24 | $-29.4M | $600.9K |
| Q4 25 | — | -33.5% | ||
| Q3 25 | — | -106.0% | ||
| Q2 25 | -278.2% | -205.4% | ||
| Q1 25 | -403.2% | -25.6% | ||
| Q4 24 | -875.3% | — | ||
| Q3 24 | -273.0% | -49.2% | ||
| Q2 24 | -371.0% | -20.5% | ||
| Q1 24 | -583.1% | 11.5% |
| Q4 25 | 0.0% | 0.2% | ||
| Q3 25 | 0.0% | 0.2% | ||
| Q2 25 | 0.3% | 9.0% | ||
| Q1 25 | 0.5% | 1.0% | ||
| Q4 24 | 16.8% | 0.0% | ||
| Q3 24 | 4.0% | 3.8% | ||
| Q2 24 | 0.2% | 18.5% | ||
| Q1 24 | 2.0% | 3.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
